Early Assessment of Cardiac Allograft Vasculopathy Risk Among Recipients of Hepatitis C Virus-infected Donors in the Current Era
Journal of Cardiac Failure · 2024
DOI: 10.1016/j.cardfail.2023.09.015 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cardiac Failure, 2024. Verfasst von Kaushik Amancherla und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Heart Transplantation, Tissue Donors, Hepatitis C, Allografts. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
BACKGROUND: Transplantation of hearts from hepatitis C virus (HCV)-positive donors has increased substantially in recent years following development of highly effective direct-acting antiviral therapies for treatment and cure of HCV. Although historical data from the pre-direct-acting antiviral era demonstrated an association between HCV-positive donors and accelerated cardiac allograft vasculopathy (CAV) in recipients, the relationship between the use of HCV nucleic acid test-positive (NAT+) donors and the development of CAV in the direct-acting antiviral era remains unclear. METHODS AND RESULTS: We performed a retrospective, single-center observational study comparing coronary angiographic CAV outcomes during the first year after transplant in 84 heart transplant recipients of HCV NAT+ donors and 231 recipients of HCV NAT- donors. Additionally, in a subsample of 149 patients (including 55 in the NAT+ cohort and 94 in the NAT- cohort) who had serial adjunctive intravascular ultrasound examination performed, we compared development of rapidly progressive CAV, defined as an increase in maximal intimal thickening of ≥0.5 mm in matched vessel segments during the first year post-transplant. In an unadjusted analysis, recipients of HCV NAT+ hearts had reduced survival free of CAV ≥1 over the first year after heart transplant compared with recipients of HCV NAT- hearts. After adjustment for known CAV risk factors, however, there was no significant difference between cohorts in the likelihood of the primary outcome, nor was there a difference in development of rapidly progressive CAV. CONCLUSIONS: These findings support larger, longer-term follow-up studies to better elucidate CAV outcomes in recipients of HCV NAT+ hearts and to inform post-transplant management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
- Departments of Surgery and Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
- Vanderbilt Transplant Center, Nashville, Tennessee.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
- Department of Cardiac Surgery, Medstar Washington Hospital Center, Washington, DC.
- Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- National Institutes of Health
- American Heart Association Inc
Zitieren
APA
Amancherla, K., Feurer, I. D., Rega, S. A., Cluckey, A., Salih, M., Davis, J., Pedrotty, D., Ooi, H., Rali, A. S., Siddiqi, H. K., Menachem, J., Brinkley, D. M., Punnoose, L., Sacks, S. B., Zalawadiya, S. K., Wigger, M., Balsara, K., Trahanas, J., McMaster, W. G., …, & Schlendorf, K. H. (2024). Early Assessment of Cardiac Allograft Vasculopathy Risk Among Recipients of Hepatitis C Virus-infected Donors in the Current Era. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2023.09.015
Vancouver
Amancherla K, Feurer ID, Rega SA, Cluckey A, Salih M, Davis J, et al. Early Assessment of Cardiac Allograft Vasculopathy Risk Among Recipients of Hepatitis C Virus-infected Donors in the Current Era. Journal of Cardiac Failure. 2024. doi:10.1016/j.cardfail.2023.09.015
BibTeX
@article{Amancherla2024,
author = {Amancherla, Kaushik and Feurer, Irene D and Rega, Scott A and Cluckey, Andrew and Salih, Mohamed and Davis, Jonathan and Pedrotty, Dawn and Ooi, Henry and Rali, Aniket S and Siddiqi, Hasan K and Menachem, Jonathan and Brinkley, Douglas M and Punnoose, Lynn and Sacks, Suzanne B and Zalawadiya, Sandip K and Wigger, Mark and Balsara, Keki and Trahanas, John and McMaster, William G and Hoffman, Jordan and Pasrija, Chetan and Lindenfeld, Joann and Shah, Ashish S and Schlendorf, Kelly H},
title = {Early Assessment of Cardiac Allograft Vasculopathy Risk Among Recipients of Hepatitis C Virus-infected Donors in the Current Era},
journal = {Journal of Cardiac Failure},
year = {2024},
doi = {10.1016/j.cardfail.2023.09.015}
}
EUVIMED